Outsmart your lung cancer
Predict and prevent recurrence with early-stage NSCLC with RiskReveal™
What is RiskReveal?
Every cancer is unique.
RiskReveal™ is a test ordered by your doctor to provide more information about your lung cancer. The test analyzes the genes in your tumor to classify your cancer as having a low-, intermediate-, or high risk of returning. Together, you and your doctor can use this information to design a treatment plan that is personalized to you.
Surgery is not always enough
Data shows non-small cell lung cancer returns in 30-50% of early-stage patients despite surgical resection.1 RiskReveal provides a means of assessing how likely it is that your cancer will come back after surgery. The test has been validated in multiple studies to identify patients with stage IA-IIA non-squamous non-small cell lung cancer that are at higher risk for disease recurrence and therefore most likely to benefit from adjuvant chemotherapy.2-4
“I think that RiskReveal is practice-changing and very important for discussions that we have with patients. I like giving patients enough information about their situation, and the pros and cons of additional treatment after their operation, so they’re loaded with the information to help them decide if they want adjuvant treatment.”
Robert McKenna, MD
Thoracic Surgeon, John Wayne Cancer Institute
RiskReveal Frequently asked Questions
Why did my doctor order this test?
Your doctor ordered the RiskReveal test to provide more information about your individual lung cancer. Even after surgical removal of early-stage lung cancer, it is thought that cancer will return for 30-50% of patients.1
RiskReveal provides a means of assessing how likely it is that your cancer will come back after surgery. This information can help you and your doctor design a treatment plan that is personalized for you.
What Do My Results Mean?
The test analyzed the genes in your tumor to classify your cancer as having a low-, intermediate-, or high-risk of returning. Patients who have an intermediate- or high-risk on the RiskReveal test may benefit from chemotherapy to reduce the risk of their cancer coming back.2
RiskReveal has been validated in multiple studies to identify patients with stage IA-IIA non-squamous non-small cell lung cancer that are at higher risk for disease recurrence and, therefore most likely to benefit from adjuvant chemotherapy.2-4
Many factors affect the risk of your cancer coming back. A low-risk result does not mean that there is no chance of your cancer returning. An intermediate- or high-risk result does not mean that your cancer will definitely come back without additional treatment. The decision to have additional treatment will depend on your unique situation and personal preference.
Does insurance cover the cost of RiskReveal?
We accept many forms of insurance, and there are no out-of-pocket costs for patients with Medicare. If you have another form of insurance, we will bill your insurance provider directly for the cost of the test. Your insurer may pay for all or a portion of the test costs, depending on your specific plan.
We are committed to making RiskReveal accessible and affordable for all. We offer a Patient Assistance Program and interest-free payment plans for qualifying patients.
Our billing specialists are here to assist you at:
1-844-662-6298
My results came back as high-intermediate, whats next?